In last trading session, Verve Therapeutics Inc (NASDAQ:VERV) saw 3.34 million shares changing hands with its beta currently measuring 1.99. Company’s recent per share price level of $11.21 trading at $0.04 or 0.36% at ring of the bell on the day assigns it a market valuation of $999.30M. That closing price of VERV’s stock is at a discount of -1.69% from its 52-week high price of $11.40 and is indicating a premium of 74.49% from its 52-week low price of $2.86.
For Verve Therapeutics Inc (VERV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Upright in the green during last session for gaining 0.36%, in the last five days VERV remained trading in the red while hitting it’s week-highest on Wednesday, 06/18/25 when the stock touched $11.21 price level, adding 0.44% to its value on the day. Verve Therapeutics Inc’s shares saw a change of 111.91% in year-to-date performance and have moved -1.49% in past 5-day. Verve Therapeutics Inc (NASDAQ:VERV) showed a performance of 157.11% in past 30-days.
Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 25.27% to its current value. Analysts have been projecting 15 as a low price target for the stock while placing it at a high target of 15. It follows that stock’s current price would drop -33.81% in reaching the projected high whereas dropping to the targeted low would mean a loss of -33.81% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -42.43% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -3.29% while estimates for its earnings growth in next 5 years are of -0.31%.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
ALPHABET INC. is the top institutional holder at VERV for having 12.35 million shares of worth $60.26 million. And as of 2024-06-30, it was holding 14.6618 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 6.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8598 of outstanding shares, having a total worth of $32.31 million.
